Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on RVNC. Piper Sandler lowered Revance Therapeutics from a strong-buy rating to a hold rating in a research note on Monday, August 12th. William Blair reiterated a market perform rating on shares of Revance Therapeutics in a report on Monday, August 12th. HC Wainwright cut Revance Therapeutics from a strong-buy rating to a hold rating in a report on Tuesday, August 13th. Guggenheim reissued a neutral rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, Needham & Company LLC lowered Revance Therapeutics from a moderate buy rating to a hold rating in a research report on Tuesday, August 13th. Ten research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Hold and an average price target of $10.50.

Revance Therapeutics Stock Down 7.7 %

Shares of NASDAQ:RVNC opened at $5.37 on Monday. The stock has a market cap of $560.37 million, a price-to-earnings ratio of -1.48 and a beta of 1.00. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $13.12. The business’s 50 day moving average is $5.37 and its 200 day moving average is $4.26.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analysts’ expectations of $66.30 million. During the same period in the prior year, the firm posted ($0.80) EPS. The firm’s revenue for the quarter was up 20.2% on a year-over-year basis.

Institutional Investors Weigh In On Revance Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVNC. Certuity LLC bought a new position in Revance Therapeutics in the second quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Revance Therapeutics during the 2nd quarter valued at $33,000. Hsbc Holdings PLC bought a new stake in Revance Therapeutics during the 2nd quarter valued at $38,000. Nisa Investment Advisors LLC lifted its holdings in shares of Revance Therapeutics by 2,167.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 18,077 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Revance Therapeutics by 52.5% during the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 7,628 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.